Axel Schonthal

Axel Schonthal, PhD, is an Associate Professor at the University of Southern California, affiliated with the Department of Molecular Microbiology & Immunology. His work centers on preclinical cancer research and anticancer drug development, particularly for brain malignancies like glioblastoma and metastatic tumors from melanoma or breast cancer. Collaborating with neurosurgeon Dr. Thomas Chen and the USC Brain Tumor Group, his lab focuses on translating laboratory findings into clinical applications through interdisciplinary approaches.

Research Focus: The Schönthal Lab develops drug conjugates such as NEO212 (Perillyl Alcohol-Temozolomide) and NEO100 for brain tumors, emphasizing mechanisms to overcome biological barriers like the blood-brain barrier. Recent work explores viral therapies (e.g., Epstein-Barr virus activation), intranasal delivery systems, and Phase I clinical trials in glioblastoma patients.

Publication Trends: His recent studies highlight innovative strategies in drug design, delivery optimization, and repurposing molecules for neuro-oncology. Key themes include targeted therapies, preclinical modeling, and bridging virology with cancer treatment.